← Back to Patent Explorer
US6068853A Expired / Lapsed US ⏱️ 0.0 years remaining

Temporally controlled drug delivery systems

Assignee: Novartis Corp
•
Filing: 1995-10-13
•
Granted: 2000-05-30
•
Expires: 2015-10-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A delivery mechanism and device for the passive periodic release of a drug or an active ingredient which avoids the need for external power sources and/or electronic controllers. By taking advantage of oscillating chemical systems, one can change the state, i.e. the pH, of a solution, a drug, enhancer or solubilizer resulting in oscillating the ability of an active ingredient to be delivered transdermally. The pH of a solution can be oscillated over a range of pH values from 2 to 10 by the reduction and oxidation (redox) reactions of salts, such as permanganates, iodates, sulfates, chlorates, or bromates. Upon activation, the delivery system conditions begin to oscillate and with it, the delivery of the active agent oscillates.

Inventors

  • 👤 Steven Andrew Giannos
  • 👤 Steven Minh Dinh
  • 👤 Bret Berner

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:15
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K9/0002

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 181 words
A transdermal delivery device for the passive, temporal or periodic control of delivery of active agents, comprising: a) a first species, which is an active agent, to be delivered from said transdermal device or a second species to be modified in situ into said first species, b) some or all of the initial reactants of an oscillation reaction such that said oscillation reaction is not initiated until desired; and c) means for separating at least one of said initial reactants from the remainder of said initial reactants prior to activation of said oscillation reaction within said transdermal device when all of said initial reactants are contained within said transdermal device prior to activation or means for introducing any of said initial reactants of said oscillation reaction which are not otherwise present in said transdermal device prior to activation; whereby said oscillation reaction can be activated by bringing together all of said initial reactants or exposing said initial reactants to an activating condition and said delivery of said first species is passively controlled in response to said oscillations of said oscillation reaction.
Claim 2
Dependent Claim 181 words
A transdermal delivery device for the passive, temporal or periodic control of delivery of active agents, comprising: a) a first species, which is an active agent, to be delivered from said transdermal device or a second species to be modified in situ into said first species, b) some or all of the initial reactants of an oscillation reaction such that said oscillation reaction is not initiated until desired; and c) means for separating at least one of said initial reactants from the remainder of said initial reactants prior to activation of said oscillation reaction within said transdermal device when all of said initial reactants are contained within said transdermal device prior to activation or means for introducing any of said initial reactants of said oscillation reaction which are not otherwise present in said transdermal device prior to activation; whereby said oscillation reaction can be activated by bringing together all of said initial reactants or exposing said initial reactants to an activating condition and said delivery of said first species is passively controlled in response to said oscillations of said oscillation reaction.
Claim 3
Dependent Claim 86 words
The device of claim 1, wherein said oscillation reaction has an initial oscillation frequency, the delivery of said active agent is sensitive to at least one reactant or product of said oscillating reaction and said oscillation frequency corresponds to an oscillation period which is no less than 1.5 times the time period necessary for a deliverable species of said active agent to be delivered under the conditions of the oscillating reaction which permit such species delivery, said delivery occurring passively once said oscillating reaction is activated.
Claim 4
Dependent Claim 14 words
The device of claim 1 wherein said oscillation reaction is a pH oscillation reaction.
Claim 5
Dependent Claim 36 words
The device of claim 1 wherein said pH oscillation reaction is selected from the group consisting of iodate-sulfite-thiourea, iodate-sulfite-thiosulfate, iodate sulfite-ferrocyanide, iodate-hydroxylamine, periodate-hydroxylamine, periodate-thiosulfate, hydrogen peroxide-ferrocyanide, hydrogen peroxide-thiosulfate-copper(II), hydrogen peroxide-bisulfite-thiosulfate, peroxodisulfate-thiosulfate-copper(II), bromite-iodide, bromate-sulfite-ferrocyanide, bromate-sulfite-thiosulfate, and manganese(II)-periodate.
Claim 6
Dependent Claim 23 words
The device of claim 1 wherein said active agent is selected from the group consisting of pharmaceutically active agents and cosmetic active agents.
Claim 7
Dependent Claim 62 words
The device of claim 5 wherein said pharmaceutically active agents are selected from the group consisting of adrenergics, antiasthmatics, antiarrhythmics, anticancer drugs, anti-AIDS medications, anti-parkinsonian drugs, anti-anginals, Alzheimer's medications, somatomedins, anti-viral agents, antisense peptides, anti-ulcer medications, PMS therapeutics, analgesics, endocrine/reproductive therapeutics, birth control medicaments, general hormone replacement therapeutics, stroke medications, antibiotics, immunizations, addiction treatments, anxiolytics, antisensitization drugs, antiirritants, contrast media, and antiinflammatories.
Claim 8
Dependent Claim 48 words
The device of claim 6 wherein said pharmaceutically active agent is selected from the group consisting of LHRH, PTH, PTH fragments, PTH analogs, somatistatin, somatistatin analogs, melatonin, insulin, IGF-I, nicotine, nitrosoureas, steroids, gastric acid inhibitors, nitrates, beta-blockers, progesterone, aldactone, seratonin, melatonin, sleep-inducing peptides, DHEA, NSAIDS, BMP, and ACTH.
Claim 9
Dependent Claim 264 words
The device of claim 2 wherein said active agent delivery sensitivity to said oscillation reaction is the result of at least one of: a) said active agent changing a deliverable species and a substantially non-deliverable or non-deliverable species in response to said oscillation reaction oscillations; b) said delivery system further containing a barrier to said active agent delivery and said barrier changing between an active agent transmissible or releasable form and a substantially non-transmissible or non-releasable form or a non-transmissible or non-releasable form in response to said oscillation reaction oscillations; c) said delivery system containing a viscosity enhancer, said viscosity enhancer changing between species which are more and less soluble, swellable, or viscous in response to said oscillation reaction oscillations, whereby available solvent for dissolution of said active agent is altered correspondingly, so that transportability of said active agent and/or concentration of active agent are modified in response to said oscillations of said oscillating active agent; d) said delivery system optionally further comprises a flux enhancer or delivery aid which flux enhancer or delivery aid changes between an enhancing form (delivery-aid form) and a non-enhancing (non-delivery-aid form) in response to said oscillation reaction oscillations whereby the delivery of active agent is modified in response to said oscillation reaction oscillations; and e) said delivery system further comprises i) a flux enhancer or delivery aid and ii) a separation barrier which separates said flux enhancer or delivery aid from said active agent, wherein said separation barrier changes between an enhancer/delivery-aid transmissible form and an enhancer/delivery-aid non-transmissible form in response to said oscillations of said oscillation reaction.
Claim 10
Dependent Claim 64 words
The device of claim 1 wherein said active agent exists in a deliverable form and in a non-deliverable variation and converts between said deliverable form and non-deliverable variation as a result of interactions with one or more chemical species which are consumed or generated in the course of said oscillations of said oscillation reactions, where such interaction is other than a change of pH.
Claim 11
Dependent Claim 66 words
The device of claim 8, wherein said viscosity enhancer is a polymer selected from the group consisting of poly(meth)acrylates, cellulosics, alginates, chitosan, starches, hyaluronic acid, collagen, poly(ethylene oxides), poly(sulfonic acid), poly(acrylamide), poly(carboxylic acid), poly(hydroxylamine), poly(phosphonic acids), poly(amino acids), poly(vinyl alcohol), iodine-doped polymers, polyesters, polyamides, polyurethanes, cyclodextrins, nonionic surfactants, gelatin gels, lecithin-ogranogels, ion exchange resins, polyelectrolytes, poly(hydroxamic acids), poly(3-carboxymethylpyrrole), borohydride exchange resins, oxidizing reagent polymers, and poly(N-vinyl-2-pyrrolidone).
Claim 12
Dependent Claim 58 words
The device of claim 8 wherein said barrier and said separation barrier are each independently selected from the group consisting of poly(siloxanes), poly(carboxylic acid), poly(sulfonic acid), poly(acylamide), poly(hydroxylamine), poly(phosphonic acids), poly(amino acids), poly(vinyl alcohol), and poly(N-vinyl-2-pyrrolidone), poly(meth)acrylates, cellulosics, alginates, chitosan, starches, hyaluronic acid, collagen, iodine-doped polymers, polyesters, polyamides, polyurethanes, ion exchange resins, polyelectrolytes, poly(hydroxamic acids), and poly(ethylene oxides).
Claim 13
Dependent Claim 72 words
The device of claim 1, comprising: a) a backing layer or laminate which is impermeable to the components of the device with which it comes in contact, b) a membrane or matrix layer through which the active agent must migrate, c) an oscillation reaction area in which an oscillation reaction can take place, once initiated, d) necessary oscillation reaction reactants; and e) an adhesive layer suitable for use in said transdermal device.
Claim 14
Dependent Claim 24 words
The device of claim 1 wherein at least one of said oscillation reaction reactants is added by a user or administrator of said device.
Claim 15
Dependent Claim 69 words
The device of claim 1 wherein all of said oscillation reaction reactants are present within said device, but at least two of said reactants are physically separated by a separation means so as to prevent said oscillation reaction from occurring, said device further comprising a means for modifying said physical separation by the action of a user or administrator of said device to allow said oscillation reaction to initiate.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-05-30 2003-11-29 2004-05-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-05-30 2007-11-29 2008-05-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-05-30 2011-11-29 2012-05-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag